10.85
8.21%
-0.97
After Hours:
10.85
Harrow Inc stock is currently priced at $10.85, with a 24-hour trading volume of 349.39K.
It has seen a -8.21% decreased in the last 24 hours and a +3.43% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $11.94 pivot point. If it approaches the $10.87 support level, significant changes may occur.
Harrow Inc Stock (HROW) Financials Data
Harrow Inc (HROW) Revenue 2024
HROW reported a revenue (TTM) of $130.19 million for the quarter ending December 31, 2023, a +46.95% rise year-over-year.
Harrow Inc (HROW) Net Income 2024
HROW net income (TTM) was -$24.41 million for the quarter ending December 31, 2023, a -73.30% decrease year-over-year.
Harrow Inc (HROW) Cash Flow 2024
HROW recorded a free cash flow (TTM) of -$148.71 million for the quarter ending December 31, 2023, a -2,351% decrease year-over-year.
Harrow Inc (HROW) Earnings per Share 2024
HROW earnings per share (TTM) was -$0.76 for the quarter ending December 31, 2023, a -46.15% decline year-over-year.
Harrow Inc Stock (HROW) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Opaleye Management Inc. | 10% Owner |
Mar 28 '24 |
Buy |
12.82 |
50,000 |
641,000 |
3,745,600 |
BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Mar 22 '24 |
Buy |
11.59 |
9,000 |
104,310 |
2,137,525 |
Opaleye Management Inc. | 10% Owner |
Mar 20 '24 |
Buy |
9.65 |
50,600 |
488,290 |
3,695,600 |
SAHAREK JOHN P. | CEO of ImprimisRx |
Mar 01 '24 |
Option Exercise |
8.75 |
5,000 |
43,750 |
254,803 |
BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Feb 20 '24 |
Option Exercise |
10.67 |
150,000 |
1,600,500 |
2,188,361 |
BOLL ANDREW R. | CHIEF FINANCIAL OFFICER |
Feb 20 '24 |
Option Exercise |
10.67 |
45,000 |
480,150 |
586,569 |
SAHAREK JOHN P. | CEO of ImprimisRx |
Feb 20 '24 |
Option Exercise |
10.67 |
30,000 |
320,100 |
262,419 |
BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Feb 07 '24 |
Option Exercise |
7.71 |
15,400 |
118,734 |
2,038,361 |
BOLL ANDREW R. | CHIEF FINANCIAL OFFICER |
Feb 07 '24 |
Option Exercise |
7.71 |
7,400 |
57,054 |
541,569 |
BAUM MARK L | Chief Executive Officer |
Nov 16 '23 |
Buy |
8.11 |
7,500 |
60,825 |
2,022,961 |
Harrow Inc Stock (HROW) Latest News
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Benzinga
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket
Benzinga
New Strong Sell Stocks for November 14th
Zacks Investment Research
About Harrow Inc
Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):